It was a pleasure to talk to Stephen Hanauer (Northwestern University Feinberg School of Medicine, Chicago, IL, US) around his presentation on ‘EMERGING IBD THERAPIES’ which was presented at the virtual 2021 Crohn’s & Colitis Congress.
- Could you give us a brief overview of the current treatment options for patients with moderate‑to‑severe ulcerative colitis and Crohn’s disease? (0:18)
- What are the current unmet needs in the treatment of patients who have had an inadequate response to prior treatment with TNF inhibitors? (1:55)
- How do you expect the use of IL‑12/23 inhibitors to develop in the coming years? (3:01)
- What are the potential advantages of oral JAK inhibitors and S1P agents, and what is the current status of their development? (3:54)
- What remaining issues need to be addressed in the treatment of patients with moderate‑to‑severe ulcerative colitis and Crohn’s disease? (5:38)
Disclosures: Stephen Hanauer has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of CCC 2021 (Virtual).
Share this Video
Related Videos In Gastroenterology
Jayne Doherty, UEG Week 2022: Response to COVID-19 vaccination in patients with inflammatory bowel disease taking TNF antagonists
In this touchIMMUNOLOGY interview, we speak with Dr. Jayne Doherty (St Vincent’s University Hospital, Dublin, Ireland) around her study, which investigated the impact of inflammatory bowel disease (IBD) and of TNF inhibitor therapy for treatment of IBD on antibody responses to vaccination against COVID-19. The abstract entitled ‘REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN […]
Gil Melmed: Research highlights in inflammatory bowel disease from 2022
In 2022, 3 therapies were approved for the treatment of the inflammatory bowel diseases Crohn’s disease and ulcerative colitis. including a JAK inhibitor, and s1P receptor modulator in UC and an IL-23 inhibitor in Crohn’s disease. Advances in research in combination therapy and personalised medicine were also at the forefront in 2022. It was a […]
Gil Melmed: Health burden and available therapies for Crohn’s disease and colitis
touchIMMUNOLOGY caught up with expert faculty member Dr. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) to learn more around the health burden of Crohn’s disease and colitis and what therapies are currently available to help manage symptoms in these indications. Questions Could you give us a brief overview of the health burden of Crohn’s […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!